Clinical Trial Update: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating venetoclax, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma (a relapsed non-Hodgkin lymphoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non Hodgkin Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Nordic Lymphoma Group | Conditions: Relapsed Non Hodgkin Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN